References
- Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041.
- Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones FA. Outpatient treatment of ulcerative colitis: comparison of three doses of oral prednisolone. Br Med J 1962;2: 441.
- Truelove SC. Treatment of ulcerative colitis with hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J 1957;2:1072.
- Gitnic B. Antibiotics and inflammatory bowel disease. In: Ginsberg AL, editor. Gastroenterology clinics of North America. Philadelphia: WB Saunders; 1989. p. 51–6.
- Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnson D, Axon ATR. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of ulcerative colitis. Gut 1985;26:1380–4.
- Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210–2.
- Burke DA, Axon ATR, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123–9.
- Mantzaris GJ, Hatzis A, Kontogiannis Ph, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43–6.
- Akamatsu H, Niwa Y, Sasaki H, Matoba Y, Asada Y, Horio T. Effect of pyridone carboxylic acid anti-microbials on the generation of reactive oxygen species in vitro. J Int Med Res 1996;24:345–51.
- Galey HF, Nelson SJ, Dubbels AM, Webster NR, Gally HF. Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med 1997;25: 1392–5.
- Baily S, Fay M, Roche Y, Cougerot-Pocidalo MD. Effects of quinolones on tumor necrosis factor production by human monocytes. Int J Immunopharmacol 1990;12:31–6.
- Turunen U, Farkkila M, Valtonen V, Seppala K. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease. Gastroenterology 1993;104:A793.
- Greenbloom SL, Steinhart HA, Greenberg GR. Ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol 1998;12:53–6.
- Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91: 328–32.
- Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas J-L, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Am J Gastroenterol 1999;94:674–8.
- Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, et al. A prospective randomized controlled trial of oral ciprofoxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454–6.
- Turunen UM, Farkkila M, Hakala K, Seppala K, Sivonen A, Orgen M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072–8.
- STSC’s PLUS*WARE 1986 Software product. Statgraphics user’s guide. Rockville, Md.: STSC.
- Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067–70.
- Peppercorn MA. Are antibiotics useful in the management of nontoxic severe ulcerative colitis? J Clin Gastroenterol 1993;17: 14.
- Lobo AJ, Burke DA, Sobala GM, Axon A. Oral tobramycin in ulcerative colitis: effects on maintenance of remission. Aliment Pharmacol Ther 1993;7:155–8.